Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) disclosed that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the final stage trial program for adult chronic/persistent immune thrombocytopenia treatment. This...
WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday
that fostamatinib, its oral spleen tyrosine kinase or SYK inhibitor, met the
primary endpoint in the first of two double-blind studies in the FIT Phase 3
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Intertape Polymer Group (ITP):